New Heart Drugs Struggle to Win Sales as Doctors Hold Back

JFIF;CREATOR: gd-jpeg v1.0 (using IJG JPEG v62), quality = 80 C   %# , #&')*)-0-(0%()(C   ((((((((((((((((((((((((((((((((((((((((((((((((((( " }!1AQa"q2#BR$3br %&'()*456789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz w!1AQaq"2B #3Rbr $4%&'()*56789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz ?$*iE6S5裌,CI*ss*t?KM!0'5NV0I)kBY&j9sJ(*p FD0> UJ9ˎƮ$o^%aDZi“~1 _qnYTZd./|U),FM~ZqԬ[e}ʁعڊ5!ݍ-6MR%,MrHf^*-UhunA[WlU ғW] ӯO?z>q4ϕ誟h'@z_:ts)jmu)˃ka+L߀*R5&~Fم%;Kj8{F?JFp7jA1g&3.U< OC /٧:ϰYw-gdI Sյ$V>_8⮝?ԛw'"6ݬ>UܸEoʜ!n&Λ>cݟf>.6H:4HR+!48Zxy3MLJ!adj < eQjorXzχ͈M>bHH7GVq*wUbci3OEi؛gzR?ٍ”xJA}j9|!XfvcW9s%#}\'lzr~Oi;Zr\Ƴl;*AbF@ֲ5mʄ|#%xvR(I Qa?ϱ`+}w4Q}6۴g4Y] `oF~' aßc(]Õ5f?'?u!;?^AT+cp!"ǪIt(A݌atAҷ"1LT  m8k=,54#ԟٞ$T׻ QF`|r[ɰ}߳?W5BmRkar,jxsĮu/5+x?]~PJM`H»%sP8DE==ZOT""_5VxS4OZ< X=H'sqw/&m6mNGHO w?ͅh؟~߸s4'_0lT?Vl^cQ0 Pprym%p&[My"5z~~}CPoƿ] }&?Qǡ˭Œ }4R l:Wp R&;/XHsT G61jOEI#5tS[l4bT6O?V}w'^e<)4fzneVoj2!6c$bvbMHOltvKXs&F&XSDѓO5i(Kke#ƒ du)dxf|ŋmkq(qH{w7IJ}Z!#|NJGj M+RaY?®Zh:O-QXbN1By>&=4x mR.kE|)Q?8G'ߏhAv`%m[T=?ҟGP]K zh_dԋhrF۩uEAvUM;NLltǥML@Q)hB+p?SaLC}O=4ÓՉZJ`!Pju'f3ݪz Lh4-2XXZ·0kNRkw=va7b 6wg\%?cavTd'<+#m H?TcLsD#} ?έBFb$xUE-CBkY{t[ƹu-ʓW*0p~( cMT\$bxܙ0v@ooX_^^A*Uf:~C}Ah"8jz2[A*E~?-=|'s?ҟVEi504e.d퍽>>ґ#jїiy)$?5Z%M+OAs6bKH]85:ivLFwL {²9X|]m&S.>b M򨮺;+4VkA*e qĿƣ f EW&~~gQ 4%K >RwU>cTZ;rk 'qk)w&W=d|j(rI?7.iX8kfrl}{S}t/5wr]FxͿ'?^1~GҀ(ӱexx?4T܇-vphk݅O $>PYYx^ɬC|i/EH)X.q'7cǵ?ͩT?Ehcvs5:Nz ce5ʅi|̚}gQ_hwm? )E9M͛9=>:_C_ޖCڵc_RQʻٖM"GҐ|N?v{detAXX(JQ )iqNzX٧ǃ+#%2ob&2HG.i>Ҋ`RP(*4]'RkOR Z(u_R d_/֊:L1KHԃ[K@ KIJ9? :Q Z))p?O#4/)E%GJH:PƄlb颤\SS') ;ԧ~શ}dZO)g8jӅj:֟M`(J)i QIN4}i&(PK@4ǟNyoH:R)Z--%8RRRn t t^-%.(h`Gޓ*Z/'TQG֒Q@PQ?KIL%-'jZ)hGj;ҊJQLFd*Jbh(R(KiLy??ʤE \F8 KE#RS|IQHQEQIiEO2I(ɢ1Jh;TrRbҐtJ(4QqFh4tۊdyʙ6_ {SiiJ9R*65Ey⨽}UNը&tʾaTFp$4gC QޝڐI $NE-?"":S80qV_Ib\:Ӽ@;2:&QL i@EsQmj7\J#N>kv›a<+9 Py bҢmAS2#ql5.Iޓ~zR)֝I}MQq?v7doʙ:0Q#P-0/t_ -S[/eրԱEQ}cLAV#pP?D^ 3W4+}b$!P8Mr2>W4Y'\Ê8vv«݄LM^=.cGZNPo*?j&i#Y_fGrK݊Zb>vJj<h?g#ik✟?MBiV/mz{U "f"+c8sS_>0?a7XcM;yn>"{gsܚh"jj6):^0yl' ~d}h=c<T'ă \Wv[mW؜XYR mG=N|@q(7s1m:cHֽoEd]ϫɓUb?*tHTSEX"5j?j(icPZ>i_`:|5Ѐo?٘.Oe|T|)\5'ß^7AS|6̓8$9j _-ӱJWRms]x'h8b?Hft6cr>ZÚ;^-aUVlWOht:~MM4['Q0sDZ;o-ӿnT-?{$15 il䵶_aQ*P(QP(s`c*L#S?.?jx8'~㣰h/!<h2`F\qIy7R=ir$菱$ME{0G!i?ٗq=|G#:[Aڽc( dVW} {~): l <?xJo.K.Ww3[v_u8;[˘ҽbhJJ"0~F+^ՏVygه<^&iR][PxiP0 \?}KguunO@ؐCXS|0hز]h3ch#5NBNsOKyVᤍ;P4*u[J18>0 ?֢X]Qj;5qlN 1|ynO{4֤ørHhɮɛ&=2>=e'T/ީaj1~[!&7GpGzkcj'WZ DƏml#|Cw{wi<6H'u|.#6r3>?n.̜;鑶p?U c*a>R|[?'JFkHxUs#W2|CMJo]t4MO^OJzBwgiFM/dML0?!ڨS}1]/]n6VJw#z죝6Ciwk_$cT=헓QkWそ2@*?lzʃP]U:ߨnQ6l?ʼx['-:ԩYc5O{Y(rG޷4%<ֿ' a/Đ#s+&bMՒe)oͨZ9s.Xw:6񾀿¢C-SXiXO?HG5^h. .[?٩KvOÛ%ۛΛ?^~%Yt~([\@4$w7Q }>?x-1i)?MDtQuI?bvzg< ϻ;Zv8Xدy٪ LWG WIϺNsJO*whv{)0{Eӫx^U; q]kܷz/ڮLJ SMe3|I'2ild&ûtƹUKpdZ~HWׇ[Ǭ%[ILu\9?ןcB jW֏5sޟ${4ևLSHbդtXwO2̾[g#AH#M;PeQ»}}E@S1'܊%FTޤHy K!t8qNel9jZH>\*DA.>]Ͼ( KA8Ng[޴(-cO7Mt5W{g]EŚZ$X`΋qV$x.\1feqOf^ݚW !u3iEP„8ST'FW4+qO1õzq=k[8K $+Ԑ: v-$2{CPTr^?.y8zU~i ҕĶ\1RT!cqVInѿݎq隸LlyGSG֗Ny5]_J;҃%gzxe"9~6\4i 4h0SJhNhRV {{5ȺE1`( ˕KsKCiXsjxڎdhځڝF=$qNst8a<W9tվU\ʦa% p Z|gYG]tqCR?r#5h9џ}sS/ĮhW{ZxoǾ+=|֧>q@qj4ݤNB?;"p#ZkU9W<^z_(m?[ƱF¨n½R5ּBFz* ƺQw @]zG40fPN7ja}bp2i#ƷwEGd<?t&ۚ68ꕭ8|ΠU*5h"[֏5V-bR9ɤWcb)~3;)#=WAIBd}S\HXɪ Ӳ(Kܾ9ϵJӣLr9)IqP,gQJ$$w4\9M5םGLPN拊ő:{Tyz~hg_CP񲺲~l皌Qw8c &ԝrSמih?j*7֦ i'Mi(iYd?|vU+!j~zT^i Yٺ6>%eQw{ҬxG XcK\MU<)rP8bڐ!*7u&iy|77/[s#mG" tºBHP?Zإh.(b Sj`ROAv҅ҁE4-8 ^=kY`o4^v'.|dxsPDk KfVV8 T*z\&hH8ީ"&dNWz-1ڗ4PJNXOiOJI~=jF6iP3iq@(< TkSխD `SOj}iOu'j_jջBqץRb7t;5O {{hWΟ9=5JeV7%٥;V-"R>Ye2GRT&V-l *\[YZ^z_/gua?~xln6ӈ^4$|ƕmmzVfۯ ݳ.--圠%,@8ӍF.Z$UaQsW$dHЎ!5-QVh#*}ma\'5ՍNq^hSb vJpN*@(8FeL6prGke_T)SO( Nm/PeN6WKw PqVW@\F΋=dlW+.Hclk0_qȪR{h ֥.8ùKީBЃhr=<ٹ]eI ~$=+Ү~zԼD 帓Z14ZgB?fC5oBmFvљ4o@yn~K{ HgOҮ2 ٕ6s/ʼ:EC? :ꊹ"5 ֖Ytû^.nEWr =kּ1xHp<8!x R0ܔ'd$1 W|K)&MA eaXǥxΕ]wWWZ[نHqqҍXaIٚixji2UO29ֵBC#:j jQ^x*Zll81r36׀W_-ݾ-bQ#2~BG+nk )46YqHET|Ĵ$vvUWl G!Tҝҷlx']Sza~[vDc˦Ei}C<u*a4e5kdJb<8+cpNAE5pJQ|0MmSJ. D y_j/=5ZwFG14ވ?֭~F mV4&n>7\>}EcR{gQ%]0~1㜒/4R\E|ZtiWK,HU:5?xB=WoeY18 RV*)B7z:K-J .-WgHϧ>٥DcRx+wAgW7Em8\k`2y2JV۹)IjVB&-1eJ&&S[uL ؜;5+9 h.7sB\ǝqj Կ^FluAóKqc[XeDFNC-YsTb勛xl^hsw}s5YEiQ'ˣCW~J}r{WOl@+mus-agZp4)x? z#o/ DoqzˑŸs$+: -_K؇z)ı>??Ҷ8=nux݀ c@Wk[6đh/{Y˅eȥ^kthޓgZ0@B,aẌ|##>wi*ȿSq^/Yit&fɶo6,q*i|E-O 7WTtk_֧|⧤L*ݼ[cr!Ӹ>XvV5`t>ppvdDS#zqt?S[QLAB.G[%#n*ODx@S?9&k'VbLnzטF,a}*M漶A(F:^ގǙJ0S$ROܬAwҺ'L[CldUO$+#Gײ|Zށ VNybAFv {N+46ֽ_6uMsՂL'{#A}}y }w}rfz'º3Y6W6ps"[԰NQZSJ(ER@sYZ`o>k7x2^,zncW)!mVQ <ԎLm^=cּGŭ_DF1YԆO^H䵊CguZOtc_7XkZ=Jk7W Gy3dtCWñKenYI;uRn|=OhŸOx#5HxI^7/2oi?ֶQ]/?Ot5խEr1Skzk=صHW0Mz+Ox- Ķ:3 GsɷIX\4R(taЂ2 c?ݾh%Μ&|,6?2+C㋷k{q$"b"zwkƷpšv*i38uPw >j"VԴ7lErjkÁOkdYڏ|7|yyL8+Y&3Î&(-(Y>=LjidB|?v͔ez0?:xctaЃ5WxOڍ c?npEksLK[u"=O2 +Rv%kgKSZյ)&+(1yH㲌IԋMdi> ЬNɵ7[UQ`P7~W5ĻUx\ǵg|m ޿igӿhA<;ǫd}^5FqXEiN>1F}ӏKjxL @)оޙ>=JG >fQ8QX7ȱ.Sa<{_2[/WtM4fE's޽xcN]/ ׆;Q1FcY֛kےNn8o7Ky*GfVk#sSYLЏ1,u5C6D(??yC/4Rؤk}V`q :2qR)}޻.?m8l7U0kq6Iڈ!쫧}6ϊtr>[o/(ēT#THk ?J|j1S;ςɒJ1a+㎽_F-pX4\?گ2H>+\OQRq׀e .xx4&Ae,Vy G?ZϵeotRзnfu[Z.:r[$%kK E\-% -[]rxT*փ^SKo"XTv[/݂!AThYOQ7AS.[Exqqez)|Q⿉WO{u-.⾭G25B^k hiGJcjPi))3^hAV@Щysl4-~LoU*cWix)踤8B$SY㕒y?ƴ*M6r?A}Kvb\f8GӒ#c>\AFQm;8!Q$}`H<+hX_:/e?d%cH}=+Rr=vd~ZԺ&=Y?¸h<1̡$ҷ}N#*@ ּgOIu.=JTيptyzxgHSŒ}L]l 2 kX2Sy?ur5&TF?k Hu}+QbVvS oB>z.wXۻكiML9kR)D?#Y2ۭAK?kъ,fyhf:y珧Z[ q|^@0?.[lÛ8p3SDLs3=*?#$;KrwWF r  GB3\T/]WU"uA xH Ԝ^E7GL.с|AP$Jd בdՕXz_C4^هĺdz]w8·gҽ h|*Ƽq Jϭz i f N$>fӑ+)u3aNRX]֠''ـm|)g$i֤_S1,aHEWu:UAZ+ZE"{44wq@Z_3槉7Tg4ӄ>!HE^ujD~Ɯ(NV$A뿳?i!i0?z+grc88jNp$؅vH}R{ Yw&þI_ ~Céq$BC.Z9?m7gJS:V6>4UW]I̋@~Y9ƽCլ"QӥZ\toc؏QЊ9;klXh;$`FFg_lܫuVS+|f%VmuJSe!>D$?־w?UE(SC^At-ZNW ;WA´7_|>jS9)|ב35mtoBi.;WQ^1!⾀`ۼ}A5xAE4+<-h3`=׵6k#"HB>ZT`Fg$n?LR疒W\!`gL›qCIh`9'Ҽ*tM{o++cV54[h;yNڥh]-l#9\ץ~s/<%jn&eUָeE: 8v+b[߱PO;l}#:Tr ߕv ~ k Fc}`W?Mtmud6s?kI+jjQO~M,BFFe@z6&VZbLr[hH'0܁q?!]^1^3bmоL;[O {cf'\U088DWCŋrtTqCR]nk|װ|7K_x]cS-H g\eƱ]onnd2".qimuԗ>ŭj:4.boCk> HWuհPzNqƼKM;8IrW#=+du**'%ş2,=ȇ*#&`t]V҈A6}s.GJ:WrwWFqwZLj}5SW^a2#oٷwv 9uщ]_~kJOfu p[kS&; կ:.oOw"?{ ?=S|MZjF{gF1ud_[x?(klH8d?CR>ZF+d|>"Aۏƺ\]o? U}J1?Σ~ui蛽E)V1qT5ojS6TɟϢ1qxq ş-kߴOQ[X+k\TƾZz~?G1;Rq@U֘?"dԿoWz6$lNt&|zsu-#kK!S]KqfHִV쟵#t1"hYAsZf9]HA(##w1΋n4-R@զi4[H&E zv<{՜wV2T1=5m`J Abh^@ fc.X:sZOuoJ =YaWb/ch7&nqws-[lxT]2Hv)ԇ)!}(oEHƵ6i3ZWPM Ҏ*O.[(N5zӍjA357,HƳߜC^~bϹj.^?sU4tݫ_7}UJa5?ơpa,Dn1ZF8iҤ_@~@Ub+Ge dcф>e3  Zx8 u63pnq:(Ajʊ7HF_hsu+d뇚IRb c~?/+ETi՝.h<9Meß{D:Ɲki%v=Beج &ҍwN/xv=jj"e00[~Lpq.ɉCsvT;m"F;Kq3e'1ZV-ɀ4A/-][:e _KhZesK(~u| z Pͤh^_6 zO1\7|Oc~#vvDv,H H?^gy6Z"[ES{??bQs!t_yFl 4QŒ Wj щp,_zO 6'WV&Qe̫>O2 iJ_k.57LQpdaB'Ȟ˩ -tLl^ł]"ѢWu_.SWCBr9q{xuM2a_9V xfi,RG6b4nT9!4Rq~ݬ3*'ֺ2?⮽oKȕ|rV?؏F-f|)^[ XbAҺ~&YPi6|ohTct Or4="~/>=x^mp *@ qRV!Kc-BSkik/PAqUnIx[-m1:O#Ⱥ?̏qRq?x^D!J1FG9JV{6G0 WúTrOYj! AʙmrVʁ]C$d\Jm%BZu ωnud}e,Xg#7ev)d{Ɣ8{(^4aG(pck?#1k2fa\~$^s^kMtb8_Bw+OJ6KlOY:.ڏ"5 I{kvŦP5)SZ wq@rIb]@!e[LċfgЃۧj/";M?q+y4Jѫ?N}{,N-/ao˹Wk < ̌⟏.ɤ>$z$%Si縐(U_e=Iەr7QKN*@r)r+L_m鷫 I3+sWs)O /;d0kRiL= u ʬ7{ҹ597tc<-k|Bi8p)/'=8om'.9HJ{qduuRPo~r"?^0Oqhzl>M/Ifmy~.,1Vi_K."z-dSatSbz;S&8&F+S?GLp\ԌF@8$V;IH4]ˀ=p9H8Tv3R6hf_^3A۲ qq/+4vT?SV[8oQ\l,dZ^IL7sҲ$v3B闏j\pA=h8CNtokNk*/nҎQ_ɿf?7͹e)`"20Aj]Z׼Us&,/Y 2<ֹ$̅[t^E 1*kF 0~W[HҼ_)MQnK{צMSk[8zRdl}8ySxƠ_j8B=GP> _X/##9'm0?JTȈRh<{:|nF7/Ye*G>nV^ψfmDQL;4i vv ߷|JRmFQVBY#@;xS 9 ~4)%݇I'@ uxKYkvF pЀ:F?jڴ7ߴ.8 Tq&_<{U|ӛ:uGH$e_wV+H h'ϖH|Ƴ-mLҴda du#ͻӊw#YEΑq*\vŦAp[Fg c<$HxgQ([B6x ܷ5h(91]32!5($ރf T~?G(3TyFSŅFyx./<g9bFOK'K#$.NK~D1 %p?k *@K8Қ} Z~+>GtǺG`k_eezV5528_Z={3ӡ+%(l}R#}y+|AՉ`٪9<ٯMO=}Z<Ԃ} ؃󜋨'R|Irn:tɞTs\KN+_Z\BDE/}q(Aem )VۂJ}+ąg'CRxOcM/l]gڃi_kė~%rtfE~x_"{Sj15΃q5m8|ǭzkᶾq5/ai>s%㙉KOC=Qoh ֟L_>^ͩn?W\朿7?-M½@~d* =OHw;gφT?!jݗt+}U,a¯¹kUjql.=1s FZ&]"^/O6/# W?N&, aOă=ŏ{L??V?LczRtiO4xM_BVIŸOUcOҭA{Tr&Zj`vQb4Bv)S>e"&݋[;'QWRTo#ƭV:pYѓ9F8CүY8F|ݣ8Eij do".jrhE?ej/-~aL2v3b$~,J@$'JƇH8m=[oݨVt|ZN֔'>hF˷9wþ;k>mSCdq!OZ:?jO[M&y)?M;\i,@""ze4uj'M'Z(47ɺ/./nq!sgֶkJ9m0U7[z*G]tYEʴǵG_Τ!sgZBԭ5S)a]jQF-7JlrO:*1obs*mJO.Fugع ztL>RN8\D8ш*>6- {rNj9]Cٳda_Rw9`r/lZOWOI֏qr:Zn'#jͿڷ<}43i~2*}=&{HHP@Z9d1@ܤy;vVV>f7 m>׈{&zNΑ%-yCU=~F|k5 hC3; We;|J?݅?†??- >ӹ^EnoR+J ç?Zxcq6?S♎@𒓯zW2=Yznzxgf{\%?Zݮ'*9Srù7%$+Q?t/BXጹբHjhw4_Z'7>5e#rݶbNᕧ>fp݅GP8ң>GV?q/[L?;lo+GފNYOU-Lt\jxM&'?YF۸,<TvNMCeO{9)\)Ui ^?OVc^#%6Y~1|y,-L %UQ`dHfVJb=2?Ҭdr~??g>cOQ{H<<%E %ߊGuS(WLc9f>/.Lj~.`.H)?_7&Yo5gFha|Dz?jQ_?ޱO* \J=/jOm:[?yWg =baT.X)'cՔ_~~fA^.)txG1:|-~oʽ( \S0/i#ϣcb"QiK_|EA z(?e%ᦈ>ڃU-LS? HG`}Fwb3YHČ;ZAo?sB=.>4{O1f_hE1\Ϲ&n2h~K+E> s4bT+5D0"XH= Ok?v@(-s~t:v>chSccL~Gx61qFii( Ҏ3JycDmg']ƒjJ0o|%]ɦ@貇8i~h䤷!1] G$_A3ZsHQ'+UОij1?&(r2eOCU-|= l!,y$']u9v3N`gcQZ~t=)j~U絴:M8ThG-O DZ}*H'G'nHEz5v>[KeK`2CQ?h}A^I>n>{*|:Ϩ[k#v*udy:l $Z/PԤ>5?Οb}~Y/rs>AkmһlQc$r rxhC;}e?WOM(As4 Ї&jUNw?ֺ P)830c(KA9Y]H_Luy>Ҥ4rGs3=4}5NWO/UA[%ҬҗUd+TE1Z,+?ϩP B l#|:ݢn) =hݢ ӆ)q@ * 2oxP1җFiiq@bR1LA?Tژ< QRJLzQK)dMO7O 1J-OM@)q 7?IM_jO b%qIAAZF~y>tTԧ@QLqK@M#Z}5@4途QE ((0?Jd}O$d=@(<֖EKKqARPMO9B8;IM8RI r9?ʬA~^A?욳n?vAQ.*#Vܩ'L#"-<EC҈lR❀ˤ ՌRr!|S\|sXweJ.(D#P)sJ ;(S@?Μi}:}(- )i1@-y1*OʘO?E .(<1ΥEO{Q ^(GJdSOK@;RQE1ZZJC ZNih)?G{ }- )sH9 (9GjQQi'֖ ړP(hRw)ZAj@j1ԀPKF(⁆0y Z1@ H܃R0OҀ ޛ})?v(-?5Z) QA):@ L.}i%/z>acQqxU\AK̻KYz:}B.xWצ'Gnu4Дo秵>Iv:3\xA_{'|BI[KC-q G?J:%/m\ g)7Tݰ@?0MY>(;vncmpsRxKv%BocyT*y~ ڞI*R=p}k'לb%6*ޙo&-;{MKâd=G[?H?'\k>u661]IƘ*=Mo?⏶_. S: u0x.bU}jgT| ֢̚0.eB91wn:+C''þ{]GPkKs,{ld^+ O?fIH:ޞm K$sMg>d~ i̹)?δx>5VOi`?Vp*|һl5kC\/ Wĺ<9^Ĥ{Qx/Qcдǥ\D#Ze}!Q+ob?{!{*^gB|׋ ?^JIAR .2 `W| ZShdj&-:-զ!SA ST+8xHq#}>!d(.? GZ\% # ]4zJ7Cڢ+Q uz_7Fџ& jn-X]o^Y?^K)O_[&9ᾷ-*QbgdW'cmG$r]DdpQy5qu!4`7>eb6Yn3MO ~ ?6rm:oiɤ &?^ n:MЅd8ӽ>fogDJc,}Wèr0IφZ2_oo=t {W?"aUkOctZN?Tr%?:9k=3W[$XD9W:hx\Q>kTe&!NSLFgL;8cyW˒-g8?pϒR#’^>2еM7k 5(6;kj6G@a?-d5 x~ӼL~N9#Vr[V5"U?#5<^ d}ƺ!o˹яL}O[}"P(O{1^z)92j'_d1dOLgz|<9*9k55qocSwj4N3}>;{Uh-ؽ?pT/Tl&=Mޚ]4WIdij Xczd}gXgqkn݇Lue- ܯa>ǩHZz=b>/֙70 z/ZGf5x[ rPv^n)K cڼwSBy~Q\ 8aX2 phsڂx8/3iӯ]O)G3-Kvz, >i=~\߿]- G.U\zS9CkAmFڵ WG;=2X`u̯Fz+kZ?憎M[_hPg5iokqp6S,һ_ A2)~$׍x%_\/OE]¥Y[aO cu ogu*Pskɣ:۟WO[$SX wPh{ =7k[z8MƘ%}6Emo?Z+u\ImU\QٜŚFt(# hL7cꐧږ{Me>y?]/$YJ>oB0}[kJx"5,>zs468%L]za;Sר^U[QxE%ơoA޸ }SofH@:|cp)Z: e y-.J>VH:Ya@SOqG[q$߾@Q^T⨒in$#W /}1}I潟-f\gyG{1ky#XV!m%e% n8NY>[dwNw^.f7`hk06oF `&#My>ճM3 }ںTH} l4=yK#̼W]b#)˦̠6?6jgN,C?2nT`|H@C6b?0bs߷ /}2X``d?7g Frb%{^Uc%R|^ʸZ=kGk208۞bUIlWI *L{v1}ȦfαhÞ Ճv8/͔W .??x}Mřo0'ĿК,$dK!}jиBJG#L vz%-.; X6 ̸BK)@_dSuh)v]uƘ<~HVz;Z Q>SIiIq|5!=f5sZ.Ρe1Y"[ XU4k|R  n_lzmλ(uIw#VH'0]N-*(FPv?tyc^_X&2]HKhP-W©n 0_[Ϝyn}zbtZcdDSJq3b<1t/{ 7~O:6x Qbu&m\ooFq\wҥ9Wʿ|)k}oIA?ٖH巳ϧ5QH24y?ܙ䬏ؘBE< lq-g%>gҪIY)( Գ})Wsgÿ$|M>W 9#?CLj՜>7}d8Ыj_ѿyDy&/_6č٭k {U)"N*Lˆ0VRZHJ#ҽ*Q1V5 ՚-R [g`;]ħ9g_{d%Etofq&#ow~. Ň91c~̤?i~ȿjrw;ZRg[QcUc2(>իuXI&¹z~cְW? jWPUćZ짒VA [Hs;9-t \ r?_hHJSeՅ*0kB/~ĝz{ד [ӎk5cdtw0ЁI`[?/ [|q$eX4 "ٯ<׵|⢧ﺩy=UvQg(hMG# UI?}ko ?u[ V+)W'?|~?[)=9v[,F=$IԒ3 Ǒkŧ\һfj^+4}WGlUKd?ֶƀu{ uF`tSq_CU~&i[Yy'R{55gȮ$Sǡ?2k.{l䎟i=vݼ:\2H =G=!*{hҞeM>IᙉOd_iu =iQZs^c1 e)cy9d%8ھ-H~?I&uqhA+4v?Ï5ՁeSFU\l+FYIW/ _J|MSP:FN\]6O5!m̑~a"g?''һdkV ؈}kɆnSiWYc(1_L崽aI惦˚B@ jrozjil4c1t`k,Pഋ!ǜYS^=8V!ޛv G{Zm|v܏/]/ǧS"w-V`!-z׎k [X%MN:5=V'-0SzЛ9O ᗊ\pWȿ yjmYP_&/O'VX3[dWTdK!?iAۏ^Gٺ MEF5TrT2iа+muz-6/Ƶt[Iٰ<;:q|-d[wq]."p,SMfcsok #H c~:WujF r<?O$!a'=r ? \aG :b]M"U? (W)+/ݣͻU$t#Xv'vb<~U^n]GQAQZ2ꏈݨxqL$uףj?<@׾BFq_sgdxJ4[RdzhwJG| # @C6}I,Fe?VVηg>qԓW8蟳'ޛDI_h1]?QҾ2W[!Rȡg][ ߅}Ki?T0<ceo^ajGMMʽj^O~Q֪iRd}qN(SZg5P55Crtk{ r+^Q krJ׀͹?;68>\j0zEWW1l@' ;9%Һz @'9q݇cYrnUϲ[3/tP_`l?'?ϊes~O2H~CjЈY?b}"%24B89뽇SL:Da 1Be#sI_=xsrĶ~on҂5/vtrij12N;85< r5kuF>7.FI=aLPt`fRUv:p8]/;KLɌD8'SbDyiL O4iqu&-'Px㷥sW1HD VT1U}r y}~5Zĺ+~^ǥK",Vag5iP˨\H೓tKpFL[GU|wV3~Hzn]K"' mӏj?D]ګc֫\ߎWt#^RehqRIFFWGn{ךx$I*8'V+NkjYCێHNЦY5bОY Atkd /OF8XJIrcҫ]SϚBj[?Ʒe*յ WV.ɞҊxZUuh<ج&I! yoWؾ?!|ON?_!_K%RܝboJ>dt6vG1?_ҫ#뼐>AԷs՟c}U6뼰PPusyg^w0[NbPO?"q\€ߧV!>G.>خ} 6g):Vl骵7["q;4NVN>dV8F} VË[1>l$L݈[MCjӚVr^@y2d~}hsGQfv Hv腹|9Jl|ÎuWKfڔ-j#7?uq|TR} f.dhUi8`1WV-kPueujg\Z,." E5? $2DP+.R<-.~k^]QXl)$ל_h%,xkHG?,>>wx+;lKn+py){ <-?k5G-އC{}NOjϠ'Ds4kp[;KRå`R;EQe>hH<;ѓמN"뮣 F8W*>^evxnX]儇g_O^wa&a?|m tjS4qcjRL A K]N/Kk[d(3s> ggv x}.ႏW}^.1SRv!#M"??}/\߿sYYO OҼ_ a+O>4ᧈmH .O=_<+lQo~.umJRxG®>)x0go2SKt91'Goc^/k>X\OvubFӃ(tW37%e+JO.H/fuF+ʚS&ҩ)g2o`:w<C$jM_,\uAd~ln;IcקOƺǝSƒqEZ?Z|a/0'J]Gjj_ĩ_/F#Zx:VcxW\]bzNxLe@KWbkO-A==qbj:rHҚ2GxS_Ɲ?4_xA0{s^'V;k.Fc?3?J-&>,Ɨzh縶I$1JyUN>u~şy'Mye})˟:0Zqm {8ʓ8Z3b[h=@qcS[y3ch>W:TtLWL?O+}'I> gWsZZI2%tf#r㑚O'}#W|40OO GUԊr9SNZ>_cD=}8g~0hD=}}<^:)>=1Z:vO9x]kI[YH>D31SjOnVHx 'F[m&.)iԙhL5HsYz]5 s#?v͂~"wZzT"3qqEqMgLUdQ)I7= P䙁}bNzs5\ 4L!+&a8֣X?Mfsmp?.u_ 1+yDx>˥u /U-ݝM9ZDgU?5eܛև)*7BV5̇,'?U~W].,-jYkN Y{1_Bi6g9zF6tI{K:QŨzEu哔C \R;O>Cԟz58ן|4?O'O /z=ȝ2N9´\ػX99#Uد2jє=%mF|D/?_!C!AMWB~(LJk( s` #vFm3^;neg]BUkT{_mX{xW V\!2{>zx+SwA(/9{rۀ+[\}RSq9-35CS^%sh<}%8Ҳ|&TrXE}y&<|\j2~Vb|$.XeN5c?z\DNFSY6o&˛RI4%c887` ̿!fS9bGT9hW) *}g3N6KiLːqC +Y%he V' :mi%G\A]Yg}6:mG\BF}zֵhMM-:5";;0sWOG-P^Cݎ0B>H2(а zբ,pvΞkˠBlA.2Y@u&2p}l?BGYRP*K?d.j֑Fڄ)'h: Ƹ%Z)kçUF~O~ ;ɳi oWqP]vf7_$`fqU5}V#G]koc5NMhe*CImܫm28!5+Y;%X^20jRdg:vX{@!D1H~ZVB kZȡԴk%ddg-zVOCav}ӼAItTR̰x}I\?1Sk5=A׋JJ_mrIaʹPpx:<6۩9FJb2t#$JEV& M'^ hד怱ƥe& ^ǭvĞh,Q4[E,~5&M[[xm,210~k˰^Ƨ7+^Jlrc<x/P[_ݛ5knY4Vz(-$@gp;r~_n n(m4m/tn^Ig7.v8<ʺ4VQFf> 'S7P*i8 & Ri\0jTڍ2ܾɻ' FPK}9t[-.[o?Z!rʛKZX(;TgLqi,:=7 ( q9^_yKbXa(Sǡ xQ5uqa1EԮdT~su&$K.aP@С95m;Z}<$@m]aռi`K OOM?Cm0@9b~~՛1I"--ws\05gWqB>*!8䚭jQt-9 a|m(o?Y'Bo+z/!R/r}Wn˿ ~*xmWq`Lg^YxwLc_꺵Q}Hn!)p x211\ =X7JX|GE<[JTџ^[|OG 2>ͥb3{[{hM3^~\t_3>ʪ]ϖ8JN{vj,ymnF2<_K֑Mo&ѷ[w,݆8lcC3S*ճvT¢QC56=Zb.wd@Y5CuU-UEek%7CԗVc u&Qodɮkdr#Eh>@ %}*Bd~?5t՘,L?^}W.WPJnaJr0?Ts ?¬ rC)&"ךOqc {sRK| FM쁠`+ ʜl=-?Dm~?#>Y!0>b$1+ȍAA%f$f)wqʆ[Q79\½M-ʼቾa51Y+4G3ݘN'}eK;{qaGq†GTG v~=ˍ #ǭ5a%bvV_Ly+,GF:5Qp*ykQAFGP+T¢s7 |$h#a(פi(jVCf\ּ/(z;j:TgkOq%F|C[o+ϷJ8ݞ9y˩=;.k2c:<}h|*T:{Rp}qQ|կ*!ZJt`G\Gd;8g[]IK7=ޟ1AMF>'|Xc+ U-%Tc`'j 2d`䑊pIXΡo|jyI9Z k`NrC+ԏZp:T1yШNP<^Qef1&i uVO/xnOF*>b7sj=lw.W#L~ 02}*"66h-mw)V$_Ne!H9ȃȁ9)6F:Ed)9q׽AG3 ^"]BsJ}h؏i180\S')]=1Њ\>q_摲T%dc#lC"PMO@g$cR֋CޔrOСF3i nrGlPF9;iJ:hO?ґ)00ZgC .sJ'jh# FFX{Zr3ggp0~i!$4<=D4瞧1 9J֙9A~HD=>ePO4OoJPC `!qJ`4($Pw7@ p9Cw`SnNVEҩ;uގ>~l:SX$i @)ёP`aF=E;<XCr:ӑc}h vNt8$sQ ( cF>`ǭ?l zt{A8O9>=)O>nn“z qJr@=)q`QR3LzRv'jlU{?zOcnfݟb[xOO39ZO/zKH:zVEۃfϽ8җ\h:.{ӸOΐh rƤ8Scix4zRJF׭.:ޔ9(KqHj@&1:ЪN8FM0ysNiÜ`֐ =E80h=(4F2x0x:$# ֔7N)[~S֑8cҗ=֏^3GCQw){Rc9$Pr:Mǂ{ьcsKgC9"`G|<~5$`LENN~cP20(䆥9 VwBN@c=q=G}%>hd(:㩡~JlObNGaN*< q@Sd5F<7ΝHE?ր1uӒ%#p*uӂg)_AR7dD 5*|1Hr}( Jjdg(-= 47}4'րNxJE#8H8GP׷' 04'ۈA?+sRqM$):4={ J88G4A֐ G?7Js@@hƦAxsצ8]siUŷY?ʸ9W%Sx!i W88{%>^?ZQ&szRQր9旌sMih8##ڜ9)C{R;fD ))ؒ.74#u> j_O@  N)[۷J !҃M88_z@?Kڛ܊p=ϭނABP1ҷssi$)W߭0 sR/oiz)4H6A@rJr0 i !:cGi'$T84ǵ*9t84OhvZpbGh@ĐGvI( P$EH${S8<Զ#Z%3K2@{n)1Kv8 ӑsץ=crO8p8,pjA =I38`9o8*ӏҚ?S;pzsJX {fd|rr{SS84Ȥ\T~4sǸrK$0sH8Z+Y1E1>u[9CӦ1UQT,Oejkw#?nS n6qZxc h|3''2g>0zBLנ`QXjNSO/do.l~*s{dTZ6>I> zQ1璢6Low7k1Nc"P]>{8n 뤚H٣bTe$z<hËH:;SZEl0$Zi ttiMC#^\÷E]=6" e{)*HZx^VtO1NB瞇rs>O.^\Hxc' |ҒA/ɍђԯ I,H9#޹A4i|n1rqsIxa\>;c71"$OrfcI|Rҝ8i/A/T9mI śpriY)pmsNU~5>p3ګݐbIKs2=fp*Zor-&p*5W!w"tiǵdXh89GC@ R{/aLǡw4> =i08"om~"EI"3EsAɦƹ4\D`t;2n֐Q5 _ R588`3EYqҁq̂Cx̸̂zJ/"+ZhāLZ.A[)H#u#J} LpE8 {ڒQA\6R7MQzT~]҂QrzkR?ZR MZ9y! q֥b)dRꊽO^iO |[]iz$--Ŭk,FXIv_~-XK )hھwsK'4jhkDL1,&B u (`Z9(y\tn_\[С!CW";9/)CQZAh7|ql( ;T0x|>ծu-%mEBW*W͞ }c璉{x"a 88Uy1oFe$[=vxӜ5G WP/` zjiεU]φF< ;GOܶ:] RUij1,?}'4i>fXO@''F'?ҫ߈sS>}:- NUGdoeQWclݼgɌ&APpp?٬kLOIsio4q+b$tZt+VL$gxU0"JY[ zDTalrSsE"/U`6}6 -S\grސHOtRy %,R;~IE$ѽ В$V dX3?Y>TdLK(&ҥƽRОx)tҢ/|.O gZ64+!xyL\ 6G[qmu7OM6 eUPI${ڽS#2_Y#zyDׅZ;/T]-~vAXZY|'䶳f(UN<|$֊# _ voHBvpAMխ)A4eF1jȠa(9ukgZ/תҼQswKciUЮ8ib5iP@Ngcھ_h xᄟ'nc=a8<^[9;Ay{1M08kx(ZTm;uCI.W$}@EsYa阽Kr\iZ6*Kse68lud%SMGmQ; aM *xj6/_JO;5xsg=?3@N6Gc":ˉX|\r8;rEe{4cBJQ !4wk ·Z29G^&W?ރ{4Z5h?),=aaWTyO*u-e6,e:|y(z|ho>ar#nq" 7r+ ƋjŴ*[⪓RzP>sF+ڱt ƖPJ"2JJ8BzW]x Dm2'.WbGQ -fI[{ڬ]rhzd5>N^o+"تUKP~ls[:iC5OCғtg.%bb@JU;9FnEgƞ, `yqƹmJq'^~X-Dĺ]=:B:]/1S5w馣&7R"ܑɼF ~uiʿD9ĎX3.'q4$ʍD+Z#+w.?4>!᧹OSճlw^F1^EQܤQzf+Y8}+IO)V0qjHw߳T~W/m_FްKfccοy7Lyd]H6xW {_枳ĎF Z/y_#VkFGEyt8Ι=?r<|팭*Dp W# 1_(x_mp:Iһ0եS2y9u>*1#Ud +xEn ?w<}kЕeFy\dh斳&nU[Y!]|c'4˓d >o^ ?}?VxD? F|S{!գ^P6U5@4{浡^݌\[z3ޗQZcǿit sGOqړT?nm33}wFͯ?7 KUUetºȢަOrZCҚdU,kiקE>' ƞ?^9sΦ9?D(_x~(ϙ{?.0?ǃ?@7j,obI=ZKI;\ˑo{rwhRkh A')T(RKVg_G] ) +DsJk<(?lsɟEPF&qi8k@HS9_ _Mo_  m&? cW3QxQsg7t Q7U#ɫ1DS*K[&Io;U/#GՕbQOJ*9y 9]?Ƒr}BaxqܟuЅpOuL]QEqOi?WwKzz95aT@Յ\c7|fxQs5+7WixOד5\N%8JX-}Id蟅DRjq+(yEA%jSL*{we>|UC٣RHFyrOi_ϭ ^csJE׫ ܟ[Q#6~2$R?F3ѫ?Ǭs+XѤ-7j{}B},Y9n͜?Ϳl١9hrb +6?綎3q]B1~֖a(?tkwdxX/fj^>Gv['F x =dfj?WMskbrV;7ojWpO27$A#u$QP9,A}_?["~!nG􊒴 ˻s{C[cV^FWu6-uŁHy=V<.1Z' x?\W/V{P}Ȥ-:i @ 2kŽ#rv7r?YHB?:׌ "$z\F[qisXpXT Ϙ'%M^a#Hd++U` zV iW*(?9ȮcJI^R\Oa5cթ x%B{Үp4΋ \Jc?ҫ xo"/r9 ܽGsSON}k8q3dj,$l__q0cZ(@׈NuK=,{uW뱌&sՍU?֘+ɪ[ʼ\|%byk҅y$V9kL:^"l#.׆sI_eJ@z#pU$2MzS#3AU=N =:a-VZT oshj4 ?bچ:5=} 珴u$u¶JSiAsZu?υQk^2x"OSWkq*p:j9(hSXI4lgךB>uF*zƥ)Յ?AVa%EzOJW*? ߅.N)Z5q2<>?uc]G5yE̓@@3I<_5Vȱ8S^dF#U^.Pz#ܽ:`L+i%+XJgźX9ȕz#CxYVʽc?Y?0הi|1ˏϥz4 f]A{XcS"ƻgO)@wK/xhm>!5qi*k\Rm-`6|[4)gZ@dN3]F\|+}QȧUhuJ}b~}n ʢ-)|pfbDS~Ӯn-h|hW18$q\NJt̐[[kk}X`8pzJ=&\vֻt3mc +^).-?)ʛv*eڣ8϶k;HHOFnt$(Alr͌q7i{ssyJUC-(J'G3Z8iq7t ?|h<}(=9L~'Z׭_R̉?gmK_Q}:=150AZM 3CcMQNwln%#_>_^~\՘T(*K]1b01SEYU6B5 Sf0aՉuЅm7=JBgx 3i+H?I]7Ew(Wb&z[h˺YPrz 7y`pY k7*vF+T&f@w=9^W/=<zw^Mni?[Wsyjk>!m_AtT}5fQ>~\5ZQ "Vm2%;|]x3P]W("mCPb(Y=dRq$^ oOWB%qԓʽc7iЕjKaԢVHֿ@ |^9r팵G7FO ^c(;0~ s/CJGD|%=3\\G.̛>^A{~  c=zz~(9.i\T㊩c{$ӻ#շVLԥ0l;iNRF*)ŲҼϺF,i+K.QKQ kŔgbZO5G/IxmO +H|H}u /zh撵s*Gz6кC斓nҰƽtv1bkYT.[GN_Zƭ|ËxGOQY }5dpgZϭܟPk xkI+IE {fI5GS_z /~?c XkSEgj|/eH#(=B>?¼Z^^iߴ_MWծm O.ٚ>*{㊼4ӫZ?gׇo+Mu(|}>\}8Miu1ng.Ӿ/mk*C$c 7NQ mC:3q_;<,jKGCc`Z{i5x$z1]B^|s<׃ӗxKKyVKIUeZ)b*T\G](s w_I+k3ww5ԿW*uWüD8\U7̎Xhnz~ sPj7&NWmܳ}S7Kxg PN95C*8ƣVk˕9Yܭ*Nz/_`yUjrdK9$`s9%ًA ac^(I7+ƕKQ[RxXcz?ZЖdYr\φHwI5VK"#ݩ'k'ᔗя᧍?R5$.N=1/ˤl6߽`s~gc={ $Jzb9VQz~ Ze'kG8Rۯj jAv "݉2MxPzyT8נҪ鬷Zdv w+##=W qxş9|YH+^2/P9W|W}s"|Uo&=Bf8VTCD?Z+h .tx%-䷗צB[d+8hEa 1՝b_/7CK_pkQxcP=.?63_ FĪJ8*爵YF$tQPv3j(M]?&s~]LJGx=~kR't$գww8 $k߄9F6-VF >$%?"^|Bk sL_q u?Q[<;o4jLEt Rm4xf9ſi#tWn7cSK_˫=c?CW PX3-|' Ag]>440 KϏCF bb7($7/y3fIdt"'Rk>+/H]X-vGzq\n.5wF~qj󥁭QCג\5cVsɥ7 n v]8L-Z|"XJg >c,VOۆҾp>3Ij)͕vgۊڡs,8隣?Ϊ[G2yX+jԧ: oM0Ms]iMuYG3c_ KpnI>zאX][ZBDr9buk4R*qp:zWjdΈ `"#]X!H3G+ O+ZHd*·^h\/@ÐA#5PEҋ﹝LG5~8,=yua^Le$(#^|dw`#@'].,eL3y!r:**J. HWL- ~̉a*[$ gҠxk:.B~Lk募2me #m]vB>k6OT`1˪iG6>$}V٭P1+)9QG=Ezφ|B!־wu-J)KۋP[ZFP@ɨm'FB)]RO0Kή#hlՍ' al+ i%rW+C4995ZVGru:ZcZH@Ъ1><?|P#BU,q{gؒĐOoYg܇W?[ZtsxGI5e7IB 3_ɖ*I#"'* GW|[ xKHj< 7i3$2ǏSNg?_YemWhO~Na7Zߌ=MhoIt$ ' ?6O'&Ӓ3[ xNֵ'HAYHֽDVcȄ u$W{xxM݉KP=n sWR{hDa6@uܖ9}RcgNEq -dl65hhz>^O + a*&ęs!xXMCSZbXQqZŗ!G͌~P3飃AUm_z]͆mGq?Uګ|% cXבH:` URF1=*?>.^nI+N2s^?_]B>(H~WlgpjV|rQ$ғlQLil5#Jr+mu7`䃌u+*BAPzsM OSIs>ڂrHP8)\TuT\7SHpp89g0`wqcC{t4i<*-#QKE=hnRk,2Ur+ֵj#!Yh/H"KD; }sZ; }b?Z(7q5s-X.ݶUcO޷c+wN>5U{ M[ J|KoĖQmQ(HШ=}*Ho*APC`4h'&:#xpZeL[7=ez̐L5 `QSiʾr񷉄qB"UIڠz뚡܃(S_e}'ΙIO$rO5=ͬb;[#E;(!;\2&0I =2MEGȧӊ({ q8imTb(l0=*@01֊)\`I9緥Qp+dJ|EK4QE+ P7c4QH bzQ@@1AE1(\"Ҋ(t֔#墊X6=( tQ@$bU= h_]$QE40dӊRd(UZkeg|tv?;$1( `IȢpM<;E#bOSɧ6q߽Pb㊑@2|Gf򧑏Š(7g'ڊ)Ųx(/+ފ(Y&!ӗ1tQBܜk(˸@vzQEcv6#ʐHh%@EqIpIQ@ :JEPJb@)^NqFGIpRNǭ$g'QN(,  6O}E$PA=E PKNzzR9_J(Ce=r~LE bsri͓E"aE7ޑ<(?
Warning: fopen(https://newsweekme.com/wp-content/uploads/2016/04/2016-03-30T074753Z_1202754765_GF10000364213_RTRMADP_3_NOVARTIS-TURKEY-780x439.jpg): failed to open stream: HTTP wrapper does not support writeable connections in /home/newsweekme/public_html/wp-includes/class-wp-image-editor.php on line 428

New heart drugs hailed as breakthrough treatments by researchers are struggling to gain traction among prescribing doctors, posing a headache for makers such as Novartis, which reported more weak sales for its Entresto medicine on Thursday. REUTERS/Arnd Wiegmann/Files

By Ben Hirschler

LONDON, April 21- New heart drugs hailed as breakthrough treatments by researchers are struggling to gain traction among prescribing doctors, posing a headache for makers such as Novartis, which reported more weak sales for its Entresto medicine on Thursday.

Novartis has touted the novel heart failure drug as a $5 billion-a-year seller and is banking on the product to help offset loss of patent protection on its blockbuster cancer medicine Glivec.

Yet first-quarter sales of $17 million were well below analyst expectations of $25-30 million and the company now predicts 2016 sales of just $200 million, or less than half of consensus forecasts compiled by Thomson Reuters Cortellis.

Novartis’ problems are not unique. Sanofi and Amgen are also battling to win prescriptions for their new so-called PCSK9 cholesterol-fighting injections Praluent and Repatha.

Such difficulties are in marked contrast to other disease areas such as cancer, where Bristol-Myers Squibb’s new treatment Opdivo is an outstanding commercial hit. Novartis’ own psoriasis drug Cosentyx is also beating expectations.

U.S. heart specialist Richard Chazal, president of the American College of Cardiology (ACC), believes slow uptake of pricey new heart drugs highlights the peculiar difficulties surrounding such medicines, which are typically given for life.

“Cost is a problem,” he said in an interview. “There is concern on the part of many clinicians that if patients are reasonably stable and one starts a new medicine then they may become discouraged by the cost and actually stop taking medication.”

The U.S. list price for Entresto is around $4,500 a year, while the PCSK9 drugs cost about $14,000.

Adding to doctors’ reticence is the lack of specific guidelines from professional bodies such as the ACC, American Heart Association and European Society of Cardiology.

While updated guidelines covering the potential use of Entresto are in the works, the delay has frustrated some experts such as Milton Packer, one of the cardiologists who led trial research into Entresto that found it cut the risk of both cardiovascular death and admissions to hospital by a fifth.

Packer complained in a journal article last month about the fact that the guideline process had so far been “silent”.

For Praluent and Repatha there is the added complication that while both drugs have been shown to reduce cholesterol dramatically, clinical trials are still ongoing to prove this will actually cut heart attacks as expected.

In the long term, most experts still predict the new clutch of heart drugs will become multibillion-dollar-a-year sellers, but it is going to be a longer haul than initially anticipated.

“We’re extraordinarily fortunate to have these wonderful new tools that science shows us can potentially improve outcomes,” said Chazal. “How to use them is something we are still working through but I think we will see increased uptake in the next 12 months.”

In a bid to invigorate Entresto sales, Novartis said it was expanding its U.S. field force of sales representatives, starting this month, and also launching a direct-to-consumer advertising campaign.

However, the combination of lower sales and increased marketing spend suggests that Entresto – arguably the Swiss company’s single biggest new drug hope – will take time to contribute significantly to the bottom line.

Social Streams

Comments

comments

Facebook Comments

Post a comment